TELA Bio Q2 FY26 net loss widens to $11.3 million; revenue drops 4% to $19.3 million

Reuters2026/08/10 20:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

TELA Bio posted Q2 revenue of USD 19.3 million, down 4% year over year on weaker OviTex PRS volumes.
Net loss widened to USD 11.3 million; operating loss widened to USD 9.3 million.
Gross margin rose 2 percentage points to 72% due to a tariff refund and a lower excess-and-obsolete inventory charge.
International revenue climbed 26% year over year; OviTex unit volume rose 12% while LiquiFix revenue increased 39%.
Heather Getz became CEO effective Aug. 4; TELA withdrew full-year 2026 revenue guidance while assessing strategy and cost alignment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608101605PRIMZONEFULLFEED9807069) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

TELA Bio Q2 FY26 net loss widens to $11.3 million; revenue drops 4% to $19.3 million

You may also like

Crypto prices